Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Nov 08, 2022 5:12pm
182 Views
Post# 35083554

RE:RE:RE:RE:Volume

RE:RE:RE:RE:Volume

To qualify for Nasdaq biotech index, company must
1. be a biotec. Onc meets thst
2. have a market cap of over 200million...not quite there yet***
3. Average daily trading volumes of 100k shares or more...close.

*** when Oncy gets to just under $4/ share, they will be eligible for biotech index inclusion.
Should they make it in!
then all ETF funds & index funds, will have to buy Oncy

Point ? If it gets to $4 and holds, that is as good as $6++
people have asked for a long time why such limited institutional ownership.
Too small & rules in place, 
should the price climb, then the rise itself will perpetuate an upward spiral.
it's called gaining traction. The recent clinical results are a great start.
 

<< Previous
Bullboard Posts
Next >>